Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Protara Therapeutics (TARA)
NASDAQ:TARA
RESEARCH TOOLSreports
Holding TARA?
Track your performance easily
TARA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.04 - $5.24
Previous Close$2.58
Volume139.87K
Average Volume (3M)177.90K
Market Cap
$53.22M
Enterprise Value-$31.37M
Total Cash (Recent Filing)$89.58M
Total Debt (Recent Filing)$4.98M
Price to Earnings (P/E)―
Beta1.72
Next Earnings
Mar 05, 2025EPS Estimate
-$0.54Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.19
Shares Outstanding20,629,772
10 Day Avg. Volume156,467
30 Day Avg. Volume177,895
Standard Deviation0.29
R-Squared0.10
Alpha-0.01
Financial Highlights & Ratios
Price to Book (P/B)0.58
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda1.76
Forecast
1Y Price Target
$25.00Price Target Upside868.99% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Protara Therapeutics News
PremiumCompany Announcements
Protara Therapeutics Reports Increased R&D Expenses
Ownership Overview
16.76% Insiders
2.86% Mutual Funds
0.14% Other Institutional Investors
76.38% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TARA FAQ
What was Protara Therapeutics’s price range in the past 12 months?
Protara Therapeutics lowest stock price was $1.04 and its highest was $5.24 in the past 12 months.
What is Protara Therapeutics’s market cap?
Currently, no data Available
When is Protara Therapeutics’s upcoming earnings report date?
Protara Therapeutics’s upcoming earnings report date is Mar 05, 2025 which is in 102 days.
How were Protara Therapeutics’s earnings last quarter?
Protara Therapeutics released its earnings results on Oct 31, 2024. The company reported -$0.5 earnings per share for the quarter, beating the consensus estimate of -$0.52 by $0.02.
Is Protara Therapeutics overvalued?
According to Wall Street analysts Protara Therapeutics’s price is currently Undervalued.
Does Protara Therapeutics pay dividends?
Protara Therapeutics does not currently pay dividends.
What is Protara Therapeutics’s EPS estimate?
Protara Therapeutics’s EPS estimate is -$0.54.
How many shares outstanding does Protara Therapeutics have?
Protara Therapeutics has 20,629,772 shares outstanding.
What happened to Protara Therapeutics’s price movement after its last earnings report?
Protara Therapeutics reported an EPS of -$0.5 in its last earnings report, beating expectations of -$0.52. Following the earnings report the stock price went up 7.265%.
Which hedge fund is a major shareholder of Protara Therapeutics?
Among the largest hedge funds holding Protara Therapeutics’s share is RA Capital Management. It holds Protara Therapeutics’s shares valued at 4M.
---
Protara Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$25.00 (868.99% Upside)
$25.00 (868.99% Upside)
Blogger Sentiment
Bullish
TARA Sentiment 100%
Sector Average 72%
Sector Average 72%
Hedge Fund Trend
Increased
By 2.3M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $384.3K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Last 30 Days ▼ 0.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
116.80%
12-Months-Change
Fundamentals
Return on Equity
-45.90%
Trailing 12-Months
Asset Growth
6.84%
Trailing 12-Months
Company Description
Protara Therapeutics
ArTara Therapeutics, Inc. is a clinical-stage company engages in developing treatments for rare and specialty diseases with significant unmet needs. Its current development programs focus on the treatment of rare diseases in structural and connective tissues and rare hepatology, gastrointestinal, and metabolic disorders. The company was founded by Jesse Shefferman in 2017 and is headquartered in New York, NY.
---
TARA Stock 12 Month Forecast
Average Price Target
$25.00
▲(868.99% Upside)
Technical Analysis
Best Analysts Covering TARA
1 Year
1 Year Success Rate
4/10 ratings generated profit
1 Year Average Return
+5.73%
reiterated a buy rating 4 months ago
Copying Andrew Fein's trades and holding each position for 1 Year would result in 40.00% of your transactions generating a profit, with an average return of +5.73% per trade.
---